Description |
Product Type |
Product Size |
Tablet |
60'S |
Product Company |
Pharma Solution |
Sorafenib 500mg |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Roche Pharma |
Atezolizumab 1200mg/20ml |
Product Type |
Product Size |
Tablet |
10'S |
Product Company |
Martin Dow |
Ondansetron 8mg |
Product Type |
Product Size |
Tablets |
30'S |
Product Company |
Beacon Pharmaceuticals |
Sorafenib 200mg |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Helix pharma |
Methotrexate 50mg/2ml
|
Product Type |
Product Size |
Tablet |
60'S |
Product Company |
Pharma Solution |
Erlotinib 150mg |
Content | Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body.
| "
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and alveolar soft part sarcoma. | Ondansetron is one of the medications most commonly used for the empiric treatment of nausea and vomiting. Ondansetron has excellent utility as an antiemetic drug, and it is effective against nausea and vomiting of various etiologies. | Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent.
| Methotrexate is an antineoplastic agent used the treatment of a wide variety of cancers as well as severe psoriasis, severe rheumatoid arthritis, and juvenile rheumatoid arthritis.
| Erlotinib is an EGFR tyrosine kinase inhibitor used to treat certain small cell lung cancers or advanced metastatic pancreatic cancers. |
Reviews
There are no reviews yet.